DBV Technologies To Present Key Scientific Publications At The American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual Conference

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BAGNEUX, France, Jan. 28, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of ViaskinĀ®, a new paradigm for the treatment of allergies, announced today that five presentations related to its proprietary technology will be presented at the 2014 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) being held in San Diego, California from February 28 to March 4, 2014. The abstracts will also be published in the February 2014 supplement of the Journal of Allergy and Clinical Immunology (JACI).

Help employers find you! Check out all the jobs and post your resume.

Back to news